Can treating a bacterial infection today reduce the chance of a cancer appearing decades later?

For Helicobacter pylori, the answer is yes—at least in populations where the question has been tested. Randomised trials show fewer stomach cancers after eradication therapy among people with confirmed infection. The harder question is how large that benefit is for an individual in Australia, where background risk is lower than in most trial settings and there is no national stomach-cancer screening program.

That distinction separates two decisions that are easily blurred: treating an infection that has been found, and inviting an entire population to look for it.

A chronic infection can alter the stomach lining over years

H. pylori is a bacterium adapted to live in the mucus layer of the stomach. Infection is often acquired in childhood and may persist for decades. Many people never develop symptoms, but the organism can produce chronic inflammation in the stomach lining.

In some people, that inflammation progresses through atrophy—loss of normal gastric glands—and intestinal metaplasia, in which the lining takes on features more typical of the intestine. A smaller proportion progress to dysplasia and gastric adenocarcinoma, the commonest form of stomach cancer. Bacterial strain, age at infection, smoking, diet, family history, ancestry and the existing state of the stomach lining all influence that pathway.

Removing the bacterium interrupts an ongoing carcinogenic exposure. It cannot erase every tissue change that has already occurred, and it does not remove other causes of cancer. This is why eradication can reduce risk without reducing it to zero.

The randomised evidence now has interpretable absolute numbers

A 2025 systematic review combined eight randomised trials involving 58,628 otherwise healthy adults with confirmed H. pylori infection. Most studies were conducted in East Asia. Participants received eradication therapy, placebo or no eradication therapy and were followed for roughly four to 26.5 years.

Stomach cancer occurred in 258 of 29,782 people assigned eradication therapy, or 0.87%, compared with 351 of 28,846 people assigned placebo or no therapy, or 1.2%. The relative risk was 0.64, with a 95% confidence interval from 0.48 to 0.84. Across those studies, about 228 infected people needed to be assigned treatment to prevent one stomach cancer, although the confidence interval ranged from 158 to 514.

The pooled result was graded as moderate-certainty evidence. When the analysis was restricted to five trials judged at low risk of bias, the estimate barely changed. Gastric-cancer deaths were also less frequent, but the absolute difference was smaller: 0.43% after eradication therapy and 0.56% with placebo or no therapy. There was no demonstrated reduction in deaths from all causes.

One trial makes the long time horizon tangible. In a high-risk region of southern China, 1,630 asymptomatic infected adults aged 35–65 were randomly assigned triple therapy or placebo. After 26.5 years, stomach cancer had occurred in 21 of 817 treated participants (2.57%) and 35 of 813 controls (4.31%). The hazard ratio was 0.57, with a confidence interval from 0.33 to 0.98.

That 1.74-percentage-point difference is important in that community. It is not an Australian forecast. Only two studies in the 2025 review were conducted outside East Asia, and the Chinese trial began in 1994 in an area selected for high gastric-cancer risk. Baseline risk determines how many cancers a given relative reduction can prevent.

A population invitation asks a different question

Evidence that treatment works after confirmed infection does not tell a health system whether it should screen everybody. A screening program also depends on who is invited, who participates, test accuracy, local infection and cancer rates, antibiotic resistance, treatment completion, confirmation of cure, cost and access to follow-up.

A large pragmatic trial in Taiwan illustrates the gap. Adults aged 50–69 were invited either to provide an H. pylori stool-antigen sample alongside a bowel-screening test or to complete bowel screening alone. Among those invited, participation differed between groups; not everyone with a positive result received antibiotics.

After about five and a half years, stomach-cancer incidence was 0.032% in the group invited to both tests and 0.037% in the bowel-screening-only group. The difference was not statistically significant in the prespecified intention-to-invite analysis. Adjusted post hoc analyses suggested fewer cancers, but no reduction in gastric-cancer mortality. The follow-up may have been too short for the full effect of interrupting a decades-long process, yet the primary result still shows that program effectiveness cannot be assumed from treatment efficacy.

What this means in Australia

Cancer Council Australia estimates that 2,584 Australians were diagnosed with stomach cancer in 2024. It identifies H. pylori as a risk factor and notes that treatment may be protective. Australia currently has no national screening program for stomach cancer.

The International Agency for Research on Cancer now provides a framework for countries considering screen-and-treat programs. It emphasises local disease burden, antibiotic stewardship, testing methods, cure confirmation, equity and health-system readiness. Those are policy requirements, not fine print.

Antibiotic treatment also has immediate costs. In the Taiwanese trial, 2.1% of antibiotic recipients reported abdominal pain or diarrhoea and 0.8% reported indigestion or poor appetite. Trial reporting of adverse effects was incomplete, and resistance patterns influence which regimens are likely to work. A failed course does not provide the same biological result as confirmed eradication.

For an Australian reader, the most useful clinical conversation is therefore specific. Has H. pylori actually been identified? Why was testing performed? Was eradication confirmed after treatment? Does family history, country of birth, previous gastric disease or the stomach lining itself place this person in a higher-risk group? These questions connect the cancer evidence to the person without turning a preventive finding into a universal screening instruction.

A short course of treatment can alter a long biological pathway. The trials support taking confirmed H. pylori infection seriously. They also show why the size of the benefit—and the case for actively searching—must begin with baseline risk and local evidence.

Sources

Evidence note: This Insight is general education, not individual medical advice. It does not recommend population screening or a particular test or antibiotic regimen. Testing and treatment decisions should be made with a qualified clinician using current Australian guidance and the person’s clinical context.